Apex Sites Present Poster on Placebo-Control Reminder Script at ASCP

Apex Sites Present Poster on Placebo-Control Reminder Script at ASCP

Apex Sites Present Poster on Placebo-Control Reminder Script at ASCP

Hassman Research Institute and CNS Research, collectively Apex Innovative Sciences, continue to study the Placebo-Control Reminder Script (PCRS), which methodically reviews with subjects the commonly-cited crucial causes of placebo response, in an effort to explore direct strategies for reducing the insidious placebo and nocebo effects within clinical trials.

At ASCP in May 2019, Cohen et al. presented data indicating that the PCRS significantly reduced the placebo effect among subjects in a major depressive episode (MDE). Since then, the same study design, including the dependent variable of depressive symptoms, was applied among subjects with a psychotic disorder. This year’s poster presents these data and the combined results from both populations with the goal of having a deeper understanding of the potential impact the PCRS has in mitigating these phenomena. The results indicate that continuous reminding of PRFs via the PCRS has powerful implications toward mitigating the placebo effect in MDD and psychosis study participants.

Download the poster: The Placebo-Control Reminder Script in Depression and Psychosis Trials: An Antidote for the Placebo and Nocebo Response

Apex sites are currently empirically investigating how the PCRS may aid in minimizing the placebo and nocebo effects in migraine trials – stay tuned for these results!

The PCRS is simple to implement within clinical trials – it has a short administration time (approximately 2-3 minutes total), uses uncomplicated language, and is streamlined procedurally. The PCRS is a proprietary, licensed document. If you would like a copy or to discuss the use of the PCRS in any research or clinical trial, please contact Bobbie Theodore at bobbie@alliancesites.com.